Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

TOPAMAX� (Topiramate) Initiated as Monotherapy in Epilepsy (TIME): A Multicenter, Outpatient, Open-Label, Study to Evaluate the Dosing, Effectiveness and Safety of TOPAMAX� as Monotherapy in the Treatment of Epilepsy in Clinical Practice

NCT00266604 is registered in ClinicalTrials.gov with Johnson & Johnson Pharmaceutical Research & Development, L.L.C. as lead sponsor.

NCT NCT00266604
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00266604 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
TOPAMAX� (Topiramate) Initiated as Monotherapy in Epilepsy (TIME): A Multicenter, Outpatient, Open-Label, Study to Evaluate the Dosing, Effectiveness and Safety of TOPAMAX� as Monotherapy in the Treatment of Epilepsy in Clinical Practice
Lead sponsor
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Phase
Phase 4
Overall status
Completed
Start date
December 31, 2005
Completion date
June 30, 2007
Enrollment
409 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

epilepsies, partial, epilepsy, epilepsy, generalized, seizures, seizures, tonic-clonic